Abstract
Background: It has been reported that compared with no local therapy (NLT), patients treated with local therapy (LT) using radiotherapy (RT) possess higher survival rate in metastatic prostate cancer (mPCa). The aim of this meta-analysis was to evaluate the impact of RT on prognosis in patients with mPCa. Methods: We retrieved the literature in PubMed, Embase, and Cochrane Library databases until June 2019 using structured search terms. Several studies were included, which evaluated patients with mPCa who received RT versus NLT. Results: A total of 14,542 patients were analyzed in 7 included papers (2 randomized controlled trials [RCTs] and 5 cohort retrospective studies [CRS]), and 2,232 mPCa patients were treated with RT and 12,310 with NLT. The data of RCTs and CRS were analyzed separately. In RCTs, RT was associated with no significant difference in overall survival (OS) (pooled hazard ratio [HR] = 0.96; 95% confidence interval [CI]: 0.85–1.09; p = 0.55; I2 = 42%) relative to NLT, while survival benefit was observed in the low-metastatic burden group (pooled HR = 0.68; 95% CI: 0.54–0.86; p = 0.001; I2 = 0%), and no survival benefit was observed in the high-metastatic burden group (pooled HR = 1.07; 95% CI: 0.92–1.24; p = 0.39; I2 = 0%). In CRS, RT results in lower cancer-specific mortality (CSM) (pooled HR = 0.49; 95% CI: 0.34–0.75; p < 0.00001; I2 = 0%) and higher OS (pooled HR = 0.61; 95% CI: 0.55–0.68; p < 0.00001; I2 = 0%) relative to NLT. Subsequent analysis demonstrated that high level of M-stage or N-stage was associated with increased CSM (pooled HR = 2.08; 95% CI: 1.69–2.55; p < 0.00001; I2 = 0% and pooled HR = 1.16; 95% CI: 1.03–1.30; p < 0.00001; I2 = 0%; respectively). Conclusions: Our observations in aggregate indicated that RT at least does not appear to be harmful and may be beneficial for low-metastatic burden patients and better condition patients. More prospective and randomized studies evaluating RT for mPCa are warranted.
References
1.
Siegel
RL
, Fedewa
SA
, Miller
KD
, Goding-Sauer
A
, Pinheiro
PS
, Martinez-Tyson
D
, et al. Cancer statistics for Hispanics/Latinos, 2015
. CA Cancer J Clin
. 2018
;65
(6
):457
–80
. 2.
Schröder
FH
, Hugosson
J
, Roobol
MJ
, Tammela
TL
, Zappa
M
, Nelen
V
, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
. Lancet
. 2014
;384
(9959
):2027
–35
. 3.
Gandaglia
G
, Karakiewicz
PI
, Briganti
A
, Passoni
NM
, Schiffmann
J
, Trudeau
V
, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer
. Eur Urol
. 2015
;68
(2
):325
–34
. 4.
Cornford
P
, Bellmunt
J
, Bolla
M
, Briers
E
, De Santis
M
, Gross
T
, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
. Eur Urol
. 2017
;71
(4
):630
–42
. 5.
Bayne
CE
, Williams
SB
, Cooperberg
MR
, Gleave
ME
, Graefen
M
, Montorsi
F
, et al. Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives
. Eur Urol
. 2016
;69
(5
):775
–87
. 6.
Yuan
Y
, Kishan
AU
, Nickols
NG
. Treatment of the primary tumor in metastatic prostate cancer
. World J Urol
. 2019 Dec
;37
(12
):2597
–2606
.7.
Löppenberg
B
, Dalela
D
, Karabon
P
, Sood
A
, Sammon
JD
, Meyer
CP
, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis
. Eur Urol
. 2017
;72
(1
):14
–9
. 8.
Dall’Era
MA
, Lo
MJ
, Chen
J
, Cress
R
, Hamilton
AS
. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer
. Cancer
. 2018
;124
(9
):1921
–8
.9.
Wang
Y
, Qin
Z
, Wang
Y
, Chen
C
, Wang
Y
, Meng
X
, et al. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis
. Biosci Rep
. 2018 Jan 17
;38
(1
):BSR20171379
. 10.
Carneiro
A
, Baccaglini
W
, Glina
FPA
, Kayano
PP
, Nunes
VM
, Smaletz
O
, et al. Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis
. Int Braz J Urol
. 2017
;43
(4
):588
–99
. 11.
Shrier
I
, Boivin
JF
, Steele
RJ
, Platt
RW
, Furlan
A
, Kakuma
R
, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles
. Am J Epidemiol
. 2007
;166
(10
):1203
–9
. 12.
Higgins
JP
, Altman
DG
, Gøtzsche
PC
, Jüni
P
, Moher
D
, Oxman
AD
, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
. BMJ
. 2011
;343
:d5928
. 13.
Stang
A
. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
. Eur J Epidemiol
. 2010
;25
(9
):603
–5
. 14.
Kirtane
AJ
, Gupta
A
, Iyengar
S
, Moses
JW
, Leon
MB
, Applegate
R
, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies
. Circulation
. 2009
;119
(25
):3198
–206
. 15.
Abdel-Rahman
O
, Cheung
WY
. Impact of prior local treatment on the outcomes of metastatic hormone-sensitive prostate cancer: secondary analysis of a randomized controlled trial
. Clin Genitourin Cancer
. 2018 Dec
;16
(6
):466
–72
.16.
Patel
DN
, Jha
S
, Howard
LE
, Amling
CL
, Aronson
WJ
, Cooperberg
MR
, et al. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: results from Shared Equal Access Regional Cancer Hospital
. Int J Urol
. 2018 Dec
;25
(12
):998
–1004
.17.
Parker
CC
, James
ND
, Brawley
C
, Clarke
NW
, Attard
G
, Chowdhury
S
, et al. Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): survival results from STAMPEDE (NCT00268476)
. Br J Cancer
. 2018
;119
(1
):37
.18.
Boevé
L
, Hulshof
M
, Vis
A
, Zwinderman
K
, Twisk
J
, Delaere
K
, et al. Pd10-10 a prospective, randomized controlled trial evaluating overall survival in patients with primary bone metastatic prostate cancer (mPCA) receiving either androgen deprivation therapy (ADT) or adt combined with concurrent radiation therapy to the prostate, final data from the HORRAD trial
. J Urol
. 2018
;199
(4S
):e231
–2
. 19.
Bianchini
D
, Estelles
DL
, Rescigno
P
, HOS
, Kolinsky
MP
, Sumanasuriya
S
, et al. Loco-regional treatment (LRT) for Ml at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): a retrospective analysis
. J Clin Oncol
. 2016
;34
(2
):280
.20.
Pompe
RS
, Tilki
D
, Preisser
F
, Leyh-Bannurah
S-R
, Bandini
M
, Marchioni
M
, et al. Survival benefit of local vs. no local treatment for metastatic prostate cancer: impact of baseline PSA and metastatic substages
. Eur Urol Suppl
. 2018
;17
(2
):e1849
. 21.
Leyh-Bannurah
SR
, Gazdovich
S
, Budäus
L
, Zaffuto
E
, Briganti
A
, Abdollah
F
, et al. Local therapy improves survival in metastatic prostate cancer
. Eur Urol
. 2017
;72
(1
):118
–24
. 22.
Culp
SH
, Schellhammer
PF
, Williams
MB
. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study
. Eur Urol
. 2014
;65
(6
):1058
–66
. 23.
Antwi
S
, Everson
TM
. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis
. Cancer Epidemiol
. 2014
;38
(4
):435
–41
. 24.
Parikh
RR
, Byun
J
, Goyal
S
, Kim
IY
. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer
. Prostate
. 2017
;77
(6
):559
–72
. 25.
Fossati
N
, Trinh
QD
, Sammon
J
, Sood
A
, Larcher
A
, Sun
M
, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study
. Eur Urol
. 2015
;67
(1
):3
–6
. 26.
Satkunasivam
R
, Kim
AE
, Desai
M
, Nguyen
MM
, Quinn
DI
, Ballas
L
, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis
. J Urol
. 2015
;194
(2
):378
–85
. 27.
Rusthoven
CG
, Jones
BL
, Flaig
TW
, Crawford
ED
, Koshy
M
, Sher
DJ
, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer
. J Clin Oncol
. 2016
;34
(24
):2835
–42
. 28.
Cho
Y
, Chang
JS
, Rha
KH
, Hong
SJ
, Choi
YD
, Ham
WS
, et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?
PLoS One
. 2016
;11
(1
):e0147191
. 29.
Bianchini
D
, Lorente
D
, Rescigno
P
, Zafeiriou
Z
, Psychopaida
E
, O’Sullivan
H
, et al. Effect on overall survival of locoregional treatment in a cohort of de novo metastatic prostate cancer patients: a single institution retrospective analysis from the royal marsden hospital
. Clin Genitourin Cancer
. 2017
;15
(5
):e801
–7
. 30.
Pompe
RS
, Tilki
D
, Preisser
F
, Leyh-Bannurah
SR
, Bandini
M
, Marchioni
M
, et al. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages
. Prostate
. 2018
;78
(10
):753
–7
. 31.
Boeve
LMS
, Hulshof
M
, Vis
AN
, Zwinderman
AH
, Twisk
JWR
, Witjes
WPJ
, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial
. Eur Urol
. 2019
;75
(3
):410
–8
.32.
Parker
CC
, James
ND
, Brawley
CD
, Clarke
NW
, Hoyle
AP
, Ali
A
, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
. Lancet
. 2018
;392
(10162
):2353
–66
.33.
Kyriakopoulos
CE
, Chen
YH
, Carducci
MA
, Liu
G
, Jarrard
DF
, Hahn
NM
, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
. J Clin Oncol
. 2018
;36
(11
):1080
–7
.34.
Boeri
L
, Sharma
V
, Karnes
RJ
. Radiotherapy for newly diagnosed oligometastatic prostate cancer
. Lancet
. 2018
;392
(10162
):2327
–8
. 35.
Gillessen
S
, Attard
G
, Beer
TM
, Beltran
H
, Bossi
A
, Bristow
R
, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017
. Eur Urol
. 2018
;73
(2
):178
–211
. 36.
Parker
CC
, James
ND
, Brawley
CD
, Clarke
NY
, Hoyle
AP
, Ali
A
, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
. Lancet
. 2018
;392
(10162
):2353
–66
.37.
Rusthoven
CG
, Jones
BL
, Flaig
TW
, Crawford
ED
, Koshy
M
, Sher
DJ
, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer
. J Clin Oncol
. 2016
;34
(24
):2835
–42
.38.
Cho
Y
, Chang
JS
, Rha
KH
, Hong
SJ
, Choi
YD
, Ham
WS
, et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?
PLoS One
. 2016
;11
(1
):e0147191
.39.
Barocas
DA
, Alvarez
J
, Resnick
MJ
, Koyama
T
, Hoffman
KE
, Tyson
MD
, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years
. JAMA
. 2017
;317
(11
):1126
–40
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
